# Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis

> **NCT02182700** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 47 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** salbutamol sulfate + ipratropium bromide

## Key facts

- **NCT ID:** NCT02182700
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-07
- **Primary completion:** 1999-12
- **Final completion:** —
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182700, "Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02182700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*